Reviewer's report

Title: A web tool for designing and conducting phase I trials using the continual reassessment method

Version: 0 Date: 10 Aug 2017

Reviewer: Akihiko Shimomura

Reviewer's report:

A manuscript entitled "A web tool for designing and conducting phase I trials using the continual reassessment method" by Wages NA et al. has showed the web tools written in R to design and implement the phase I trial based on continual reassessment method. It could be the interesting knowledge for clinicians and statistician who involved to phase I trials. After some points are to be revised, the article has enough quality for publication for BMC Cancer.

Major comment:

Many part of "Methods" should be moved to the Introduction (e.g. P5L8-14). "Methods" should be simple and easy to understand.

In this article, "the web tools" have not validated. For clinical use, these tools have to be validated by using the data from real phase I trials. The authors should reveal concordance rate of MTD between the dose which estimated by the tool and the dose determined by the trials. In safety view, number of DLT in each dose should be compared between from web tools and real world data.

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

No

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

No

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes
Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I recommend additional statistical review

Quality of written English
Please indicate the quality of language in the manuscript:

Acceptable

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests.

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments
which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal